PharmaShots | Incisive News in 3 Shots

Subscribe Now

libtayo

PharmaShots Interview: Dr. Ahmet Sezer, Karl Lewis, and Regeneron's Israel Lowy Share Insights on Libtayo (cemiplimab) for NSCLC & BCC

PharmaShots Interview: Dr. Ahmet Sezer, Karl Lewis, and Regeneron's Israel Lowy Share Insights on Libtayo (cemiplimab) for NSCLC &...

September 29, 2021

PharmaShots Interview: Dr. Krishnansu S. Tewari and Israel Lowy Share Insight on P-III Data of Libtayo Presented at ESMO Virtual Plenary

PharmaShots Interview: Dr. Krishnansu S. Tewari and Israel Lowy Share Insight on P-III Data of Libtayo Presented at ESMO Virtual P...

July 28, 2021

Regeneron and Sanofi's Libtayo (cemiplimab) Receive the EC's Approval as 1L Treatment for Advanced NSCLC

Regeneron and Sanofi's Libtayo (cemiplimab) Receive the EC's Approval as 1L Treatment for Advanced NSCLC

June 25, 2021

PharmaShots Interview: Dr. Sezer, Peter C. Adamson and Israel Lowy Share Insight on the US FDA's Approval of Libtayo (cemiplimab) in Patients with NSCLC with High PD-L1 Expression

PharmaShots Interview: Dr. Sezer, Peter C. Adamson and Israel Lowy Share Insight on the US FDA's Approval of Libtayo (cemiplimab)...

March 30, 2021

Regeneron Collaborates with BioNTech to Advance the Combination of FixVac and Libtayo (cemiplimab) in Melanoma

Regeneron Collaborates with BioNTech to Advance the Combination of FixVac and Libtayo (cemiplimab) in Melanoma

August 3, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us